Welcome to our dedicated page for Cumberland Pharmaceuticals news (Ticker: CPIX), a resource for investors and traders seeking the latest updates and insights on Cumberland Pharmaceuticals stock.
Cumberland Pharmaceuticals Inc. develops, acquires and commercializes branded prescription pharmaceutical products for hospital acute care, gastroenterology and oncology markets. Company news commonly covers operating results, product-portfolio updates and regulatory developments for FDA-approved brands such as Caldolor, Sancuso and Vaprisol.
Recurring updates also address Caldolor indication activity, Sancuso educational and commercial resources, and clinical or regulatory disclosures tied to Cumberland's ifetroban programs in systemic sclerosis, Duchenne muscular dystrophy-associated cardiomyopathy and idiopathic pulmonary fibrosis. Capital-structure items, material agreements and shareholder voting matters appear alongside the company's financial and portfolio updates.
Cumberland Pharmaceuticals (Nasdaq: CPIX) will release its Q2 2026 financial results and a broader company update after market close on Tuesday, August 4, 2026. Management will host a conference call at 4:30 p.m. Eastern Time that day, with replay available for one year.
Cumberland describes itself as a Tennessee-based biopharmaceutical company focused on innovative treatments for rare diseases. According to the company, its late-stage Phase 2 clinical programs are evaluating ifetroban in patients with Duchenne Muscular Dystrophy, Systemic Sclerosis, Idiopathic Pulmonary Fibrosis and Cancer Metastasis.
Cumberland Pharmaceuticals (Nasdaq: CPIX) declared a special cash dividend of $1.50 per share, payable on July 31, 2026 to shareholders of record on July 23, 2026. The move follows a Strategic Transaction with Apotex Health, through which Cumberland received $100 million in cash and may receive up to $11 million more for inventory and transition services.
The Board also authorized an open-market share repurchase program of up to $5 million and several Board members plan additional share purchases. Cumberland will focus resources on developing ifetroban across multiple Phase 2 programs in rare and progressive diseases. The release also corrects prior references to the record date.
Cumberland Pharmaceuticals (Nasdaq: CPIX) declared a special cash dividend of $1.50 per share on its common stock, payable on July 31, 2026 to shareholders of record on July 10, 2026. The move follows a strategic transaction with Apotex Health, under which Cumberland received $100 million in cash plus up to $11 million in additional potential payments.
The board also authorized an open-market share repurchase program of up to $5 million and noted that several directors plan new share purchase plans. Cumberland will focus resources on developing ifetroban across multiple Phase II programs targeting rare and serious diseases, while retaining significant liquidity and its majority stake in Cumberland Emerging Technologies.
Cumberland Pharmaceuticals (Nasdaq:CPIX) closed a strategic $100 million cash transaction with an Apotex subsidiary, transferring its branded U.S. pharmaceutical line after receiving over 99% shareholder approval. Cumberland retains its late-stage pipeline and majority interest in Cumberland Emerging Technologies.
The company will focus resources on developing ifetroban across multiple Phase 2 programs in Duchenne Muscular Dystrophy cardiomyopathy, Systemic Sclerosis, Idiopathic Pulmonary Fibrosis, and high-risk solid tumors, supported by FDA orphan, rare pediatric disease and Fast Track designations.
Cumberland Pharmaceuticals (NASDAQ:CPIX) presented updated Phase 2 FIGHT DMD ifetroban data for Duchenne cardiomyopathy at the 2026 Parent Project Muscular Dystrophy conference.
According to Cumberland, high‑dose ifetroban showed a 5.4% LVEF improvement, favorable 36‑month safety, and biomarker shifts suggesting reduced cardiac injury and enhanced tissue repair, with all completers entering open‑label extension.
RedHill Biopharma (NASDAQ:CPIX) closed a private placement of 8,571,429 ADSs (or equivalents) plus series A-1 and A-2 warrants at a combined $0.70 per ADS. The deal provides about $6 million gross upfront, with up to $13.4 million additional potential proceeds from warrant exercises.
According to RedHill, funds are expected to support near-term liquidity and a possible acquisition of commercial-stage, revenue-generating pharmaceutical assets, though no definitive agreement exists and there is no assurance any acquisition or warrant exercise will occur.
RedHill Biopharma (CPIX) entered a definitive agreement for a private placement of 8,571,429 ADSs (or equivalents) plus series A-1 and A-2 warrants at a combined price of $0.70 per ADS. Gross proceeds are expected to be about $6 million, with up to $13.4 million more if all warrants are exercised.
The deal is expected to close on June 22, 2026. According to RedHill, proceeds will fund a potential strategic product acquisition and support working capital, R&D and general corporate purposes.
RedHill Biopharma (ticker: CPIX) announced that the FDA granted rare pediatric disease designation to opaganib for treating neuroblastoma, in addition to existing orphan drug designation.
Benefits may include a Priority Review Voucher, potential seven years' marketing exclusivity, fee waivers, tax credits and accelerated review, if approved.
RedHill Biopharma (Nasdaq:CPIX) has begun recognition and enforcement proceedings in Korea for a New York Supreme Court final judgment against Kukbo totaling about $10.9 million.
The judgment, including roughly $8.9 million principal and $1.95 million legal fees with 9% interest, is final and no longer appealable.
Cumberland Pharmaceuticals (Nasdaq:CPIX)/b) and reported positive Phase 2a data for ifetroban in patients with high-risk solid tumors. The trial met its primary endpoint, showing safety and tolerability, and delivered encouraging secondary signals in distant metastatic recurrence and deaths due to metastatic disease, supporting further development.